A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Status:
Completed
Trial end date:
2017-11-27
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, uncontrolled, multiple ascending dose (MAD) study to
evaluate mainly the safety and tolerability of 12-week repeated intravenous administration of
E6011. A total of 24 subjects will enroll into four cohorts. Six subjects per cohort will
receive repeated intravenous administration of E6011.